Grass allergic patients in Germany are the first to benefit from new vaccine

November 29, 2006

Grass allergic patients in Germany are the first to benefit from new vaccine

ALK-Abell has launched its tablet-based vaccine against grass pollen allergy, Grazax, in Germany. Grazax is the first allergy tablet to address the underlying cause of grass pollen allergy and not just the symptoms.

The vaccine will subsequently be introduced in other European markets, beginning with countries where ALK-Abell has affiliates. The company's efforts in these major markets will focus on serving physicians who work extensively in the field of allergy. The timing of the launch varies from country to country depending on price and reimbursement negotiations with the respective authorities.

Grazax is a fast-dissolving, once-daily immunotherapy tablet for home administration. It works by inducing a protective immune response, which reduces and potentially halts the allergic reaction to grass pollen. Treatment with Grazax should be initiated at least eight weeks prior to the expected start of the grass pollen season.

The efficacy and safety of the vaccine has been documented in the largest clinical study programme ever conducted within allergy vaccination. The studies show that 82% of the patients treated with Grazax felt 'better' or 'much better' in the first treatment season compared with previous seasons.

ALK-Abell expects that the vaccine will primarily be used for patients suffering from moderate to severe allergic rhinitis who are currently not satisfied with their treatment.

At least 45 million people in Europe suffer from grass pollen allergy in the shape of allergic rhinitis (hay fever) or allergic asthma - or both. Hay fever is a chronic condition, which, if left untreated, can lead to the development of asthma and new allergies.

www.alk-abello.com

Related Content:

Drug Delivery | Development